ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.
- NMN cannot cross the cell membrane directly and must first be converted to nicotinamide riboside or NR, making NR a more efficient nicotinamide adenine dinucleotide (NAD+) precursor.
- Supplementation with Niagen is backed by over 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 40 owned and licensed patents.
- The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
- ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen.